Article Text

SAT0156 Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicentre Study in 34 Patients
  1. C. Fernández Díaz1,
  2. E.C. Cervantes2,
  3. S. Castañeda3,
  4. B. Flores-Robles4,
  5. P.E. Carreira5,
  6. O. Maiz6,
  7. M. Rodriguez Gomez7,
  8. F.J. Narvaez8,
  9. J. Blanco-Madrigal9,
  10. N. Mena10,
  11. S. Rodriguez11,
  12. F. Ortiz12,
  13. R. Expόsito-Molinero13,
  14. J.A. Bernal14,
  15. C. Delgado15,
  16. D. Palma16,
  17. A. Urruticoechea-Arana17,
  18. A. Ruibal18,
  19. C. Fito-Manteca19,
  20. V. Mora-Cuesta1,
  21. N. Palmou1,
  22. J.L. Hernandez1,
  23. R. Blanco1
  1. 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander
  2. 2Rheumatology, Clinic Hospital Santiago de Compostela, Santiago
  3. 3Rheumatology, Hospital la Princesa
  4. 4Rheumatology, Hospital Puerta del Hierro
  5. 5Rheumatology, Hospital 12 de Octubre, Madrid
  6. 6Rheumatology, Hospital de Donostia, Donostia
  7. 7Rheumatology, Hospital Ourense, Ourense
  8. 8Rheumatology, Hospital Bellvitge, Barcelona
  9. 9Rheumatology, Hospital de Basurto, Bilbao
  10. 10Rheumatology, Hospital Malaga, Malaga
  11. 11Rheumatology, Hospital Gemans Trias i Pujol, Badalona
  12. 12Rheumatology, Hospital la Fe, Valencia
  13. 13Rheumatology, Hospital Laredo, Laredo
  14. 14Rheumatology, Hospital de Alicante, Alicante
  15. 15Rheumatology, Clinic Hopital Lozano Blesa, Zaragoza
  16. 16Rheumatology, Hospital Rafael Menendez, Lorca
  17. 17Rheumatology, Hospital Can Misses, Ibiza
  18. 18Rheumatology, Hospital Universitario de Alava, Alava
  19. 19Rheumatology, Hospital Universitario de Navarra, Pamplona, Spain


Background Rheumatoid arthritis (RA) may associate with Interstitial Lung Disease (ILD). Disease-modifying anti-rheumatic drug (DMARD) or TNF alfa inhibitors (iTNF), had been involved in the ILD development as well as exacerbation of an existing one. Nowadays there is no consensus related to treatment.

Objectives The aimed of this study is to evaluate efficacy and safety of Abatacept (ABA) treatment in patients with AR and ILD.

Methods Multicentre study in patients with RA and ILD associated were treated with ABA. ILD was diagnosed by High Resolution Computed Tomography (HRCT). ABA was used at dose of 10 mg/kg/4 weeks iv or 125 mg/week sc. Its efficacy was evaluated according to the following measures:

a) Dyspnea classified by the Modified Medical Research Council (MMRC); Significant variability of 1 point and asymptomatic MMRC=0;

b) Pulmonary function test (PFT); Significant oscillations >10% in Forced Vital Capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >10%;

c) Imaging technique (HRCT);

d) Joint assessment (DAS28).

Quantitative variables were expressed as mean ± SD or as median (interquartile range) and compared with (Wilcoxon test) (Test Fisher) between the baseline and 3, 6 and 12 months.

Results 34 individuals were included (19 women /15 men), patients with ILD associated to RA, with a mean age of 61,4 ± 9,8 years. The median duration of RA before ADA was initiated was 4,8 [0,86–13,12] (0–25) years, and had previously received an average 1,29±0,90 DMARDs. RA was seropositive in 24 cases (71%). ILD was associated with a DMARD: MTX (n=3), Etanercept (n=3), Adalimumab (n=3) y Certolizumab (n=1).

ABA was used in monotherapy in 14 patients and combined with other immunosuppressors in 20 patients: Leflunomide (LFD) (n=7), LFD and cyclosporine (n=1), Sulfasalazine (n=1), MTX (n=2), MTX with LFD (n=1), hydroxychloroquine (n=5), Hydroxychloroquine with LFD (n=2), Azathioprine (n=1).

A significant improvement of dyspnea was observed; patients who didn't have dyspnea, kept asymptomatic. FVC and HRCT showed a significant improvement during 6 to 12 months period. DLCO remained stable in the majority of the patients. RA (DAS28) activity also improved.

After follow up of 12,82±7,48 months, the most significant adverse effects were: pulmonary Infection (n=2), urinary infections (n=1), infusion reactions (n=1).

ABA was discontinued due to: Serious infections (n=2); join inefficacy (n=2), pulmonary inefficacy (n=1), infusion reaction (n=1).

Conclusions ABA seems to be an effective and relatively safe treatment in patients with RA and associated ILD. This data should be verified again in prospective and randomized studies.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.